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Background: Under inflammatory conditions or during tumor progression macrophages acquire distinct phenotypes,
with factors of the microenvironment such as hypoxia and transforming growth factor β (TGFβ) shaping their functional
plasticity. TGFβ is among the factors causing alternative macrophage activation, which contributes to tissue regeneration
and thus, resolution of inflammation but may also provoke tumor progression. However, the signal crosstalk between
TGFβ and hypoxia is ill defined.
Results: Exposing human primary macrophages to TGFβ elicited a rapid SMAD2/SMAD3 phosphorylation. This early
TGFβ-signaling remained unaffected by hypoxia. However, with prolonged exposure periods to TGFβ/hypoxia
the expression of SMAD2 declined because of decreased protein stability. In parallel, hypoxia increased mRNA
and protein amount of the calpain regulatory subunit, with the further notion that TGFβ/hypoxia elicited calpain
activation. The dual specific proteasome/calpain inhibitor MG132 and the specific calpain inhibitor 1 rescued
SMAD2 degradation, substantiating the ability of calpain to degrade SMAD2. Decreased SMAD2 expression
reduced TGFβ transcriptional activity of its target genes thrombospondin 1, dystonin, and matrix metalloproteinase 2.
Conclusions: Hypoxia interferes with TGFβ signaling in macrophages by calpain-mediated proteolysis of the central
signaling component SMAD2.
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Macrophages are found throughout the body, where they
contribute to tissue homeostasis and orchestrate innate as
well as adaptive immune responses. They display a re-
markable plasticity, which allows them to change their
functional repertoire with regard to the environment they
are facing. Numerous sub-phenotypes are described.
Based on distinct functional roles and marker expression
profiles an operative useful but over-simplifying nomen-
clature categorizes classical, i.e., pro-inflammatory and al-
ternatively activated macrophages [1]. An alternatively
activated macrophage phenotype is elicited by
interleukin-4 (IL-4), IL-10, or transforming growth fac-
tor ß (TGFß), which are produced by helper 2 or regu-
latory T cells, tumor cells, or macrophages themselves* Correspondence: b.bruene@biochem.uni-frankfurt.de
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Monocyte-derived macrophages and tissue resident mac-
rophages are found in tumors. These tumor-associated
macrophages are known to support cancer progression ra-
ther than mounting anti-cancer responses. This tumor-
supporting phenotype is elicited by cytokines like TGFß
[2].
TGFß controls proliferation, differentiation, and fosters
fibrosis. TGFß binds to transforming growth factor recep-
tor 2 (TGFΒR2), which recruits and phosphorylates trans-
forming growth factor receptor 1 (TGFΒR1), thereby
activating downstream signaling [3]. SMAD proteins
mediate canonical TGFß signaling, while the PI3K-AKT,
MAPK pathway conveys non-canonical signals [4]. The
canonical pathway phosphorylates regulatory SMADs via
receptor activation. In macrophages stimulation with
TGFβ predominantly activates the regulatory SMAD2 and
−3 but activation of SMAD1 and −5 was also observed [5].
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for nuclear translocation and activation of transcription
[3]. SMAD7 is an inhibitory SMAD, which negatively con-
trols this pathway.
TGFß plays a substantial role in tumor progression,
acting both as a tumor suppressor and tumor promoter
[6]. Early in tumorigenesis, TGFß arrests the cell-cycle,
which is SMAD-dependent. With tumor progression,
tumor cells often harbor inactivating mutations in the
TGFß pathway, allowing them to overcome these growth-
inhibitory effects. In the tumor microenvironment, TGFß
responsive cells secret cytokines and enzymes to promote
EMT (epithelial mesenchymal transition), angiogenesis,
tumor invasion, and metastasis. Besides, TGFß also re-
cruits and activates immune cells [7]. Of particular interest
is the induction of an alternatively activated macrophage
phenotype, which promotes tumor development [8, 9].
TGFß-recruited macrophages are highly phagocytic for
aberrant cells and thereby decrease the ability of tumor
antigens to be delivered to the adaptive immune system
[10]. Inhibition of NF-ĸB in TGFß-polarized macro-
phages accounts for their reduced ability to produce
pro-inflammatory cytokines [7, 11].
At sites of inflammation, like in tumors, macro-
phages face hypoxia. Hypoxia promotes angiogenesis,
fibrosis, and immune suppression [12]. Activation of
the hypoxia-inducible factor (HIF) conveys many re-
sponses to hypoxia, by altering transcriptional outputs.
HIF is a heterodimeric transcription factor composed
of an ubiquitously expressed β-subunit and an oxygen-
sensitive α-subunit [13, 14]. Three HIF-α subunits are
identified in the human genome (HIF-1α, HIF-2α or
EPAS1, and HIF-3α), which all share the oxygen-
dependent degradation domain (ODD). In well-
oxygenated tissue specific prolyl hydroxylases hydroxyl-
ate the ODD of the α-subunit, allowing their recogni-
tion by the von Hippel-Lindau tumor suppressor and
subsequent proteosomal degradation [13, 14]. Under
hypoxic conditions HIF-α is stabilized, translocates to
the nucleus and thus, promotes transcription of target
genes to induce angiogenesis, ensures cell survival, re-
stores oxygen homeostasis but also promotes fibrosis
[15]. These functions overlap with TGFß-signaling, in-
dicating some signal crosstalk [6, 12, 16]. In renal epi-
thelial cells and prostate cancer cells TGFß provokes
HIF-1α accumulation, which in turn enhances expres-
sion of common target genes [17, 18]. In contrast,
TGFß alone failed to accumulate HIF-1α in macro-
phages [19] even though the prolyl-hydroxylase-2 and
−3 (PHD2/3) mRNA were decreased [20]. Although
macrophages play an important role in fibrosis and im-
mune suppression the impact of hypoxia on TGFß-sig-
naling in macrophages is poorly understood. We
provide evidence that TGFß-signaling under hypoxia isimpaired, due to calpain-mediated SMAD2 degradation
in macrophages.
Results
Hypoxia attenuates TGFß-induced SMAD2 activation in
macrophages
Macrophages in the tumor microenvironment are ex-
posed to hypoxia and TGFß but their signaling crosstalk
has not been explored in detail. Therefore, we time-
dependently stimulated primary human macrophages
with 10 ng/mL TGFß under normoxia vs. hypoxia and
followed phosphorylation of SMAD2 (p-SMAD2) and
SMAD3 (p-SMAD3) by Western blot analysis. Resting
macrophage did not show SMAD2 phosphorylation
(Fig. 1a, b), whereas TGFß provoked a rapid SMAD2
phosphorylation within 15 min. Phospho-SMAD2 reached
its maximum after 1 h both under normoxia and hypoxia.
After 4 h, the level of p-SMAD2 gradually declined under
hypoxia compared to normoxia. These differences became
significant after 8 h (Fig. 1a, b). In contrast, the amount of
p-SMAD3 rapidly increased upon TGFß addition, with
phosphorylation not being affected by hypoxia. Although
we noticed declining levels of p-SMAD3 at 4 to 8 h, this
occurred irrespective to the presence or absence of oxygen
(Fig. 1c, d). Apparently, in TGFβ-stimulated macrophages,
only SMAD2, but not SMAD3, was sensitive to hypoxia.
To explore this response for longer incubation times, we
stimulated cells with TGFβ for 8 to 24 h at 20 % or 1 %
O2. We observed decreased SMAD2 phosphorylation
comparing 8 to 16 or 24 h, an effect drastically enhanced
by hypoxia (Fig. 1e, f ). Using an antibody to detect total
SMAD2 protein showed a progressively reduced expres-
sion under hypoxia from 8 to 24 h (Fig. 1e, g). Apparently,
hypoxia reduced phosphorylation of SMAD2 at 8 to 24 h
following TGFβ-stimulation because of reduced SMAD2
protein expression.
A decrease in SMAD2 under hypoxia is unrelated to
TGFΒR2 or SMAD7
Several publications link SMAD activation to its subse-
quent degradation [21, 22]. Therefore, we started to
validate TGFΒR2 and SMAD7 as potential HIF target
genes that were previously identified by ChIP-Seq and
mRNA array experiments [23]. TGFΒR2 is the receptor
subunit that binds TGFß and phosphorylates the co-
receptor TGFΒR1 to initiate intracellular signaling. An
altered expression level of TGFBR2 will alter the ratio of
TGFβ to its receptor, thereby modulating downstream
signaling. SMAD7 is an inhibitory SMAD, which com-
petes with SMAD2/3 at the TGFß receptor to control
TGFß signal transmission. Increased expression under
hypoxia may reduce SMAD2 activation. First, we vali-
dated microarray data by quantitative PCR 8 h after
TGFß and/or hypoxia stimulation and verified hypoxic
Fig. 1 Hypoxia attenuates TGFß-induced SMAD2 phosphorylation in macrophages. Time-dependent Western blot analysis b, d and the corresponding
statistical evaluation a, c of SMAD2 a, b and SMAD3 c, d phosphorylation in human primary macrophages exposed to TGFß under normoxia (−; nor) or
hypoxia (1 % O2; hy). Macrophages were exposed to TGFß under normoxia vs. hypoxia for 8, 16, and 24 h, followed by (e) Western blot analysis of total
SMAD2 and SMAD2 phosphorylation and corresponding statistical analysis f, g. Tubulin served as a loading control
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of HIF-1α or HIF-2α, which was verified by Western
blot analysis (Additional file 1: Figure S1A, B), reduced
hypoxic TGFBR2 mRNA induction. mRNA expression
of TGFBR2 under hypoxia/TGFß was lower compared
to the hypoxic response. In contrast, SMAD7 was pre-
dominantly induced by TGFß, with the signal not being
altered by a HIF-knockdown (Fig. 2b). Hypoxia only
showed a small mRNA induction of SMAD7, whileinduction by hypoxia/TGFß was comparable to TGFß
alone. A knockdown of either HIF-1α or HIF-2α slightly
reduced hypoxic induction of SMAD7 and significantly
reduced induction by hypoxia/TGFß, suggesting the in-
volvement of HIF in hypoxic SMAD7 mRNA regulation.
To determine the impact of hypoxia on TGFΒR2 pro-
tein expression, we examined its surface appearance
after 8 h by flow cytometry (Fig. 2c, d). TGFΒR2 expres-
sion was neither altered by TGFß nor by the
Fig. 2 Expression of TGFBR2 and SMAD7 in response to TGFß/hypoxia. Macrophages were transfected with non-targeting siRNA constructs (ctr),
siRNA-HIF1α (si1α), or siRNA-HIF2α (si2α) and mRNA expression of TGFBR2 a or SMAD7 b were analyzed by quantitative PCR after treatments with
TGFß under normoxia (nor) or hypoxia (hy) for 8 h. c Cell surface expression of TGFBR2 was followed by flow cytometry after stimulation of
macrophages with TGFß under normoxia (nor) vs. hypoxia (hy) for 8 h and d mean fluorescence intensity was calculated from 4 individual experiments.
e, f Time-dependent Western blot analysis and statistical evaluation of SMAD7 expression in macrophages exposed to TGFß under normoxia or hypoxia.
g, h Macrophages were exposed to the phosphatase inhibitor okadaic acid (OA) 1 h prior to adding TGFß for 8 h. Phosphorylation and total protein
expression of SMAD2 was followed by Western blot analysis, using tubulin as a loading control
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Fig. 3 SMAD2 protein stability is reduced in response to TGFß/
hypoxia. a mRNA expression of SMAD2 followed by quantitative
PCR in macrophages stimulated for 8 h with TGFß under normoxia
(nor) vs. hypoxia (hy). b Macrophages were stimulated with TGFß
for 4 h, followed by the addition of cycloheximide for 0 h to 4 h
and subsequent Western blot analysis of SMAD2 expression. c Half-life
determination of SMAD2 in TGFß-stimulated macrophages under
normoxia (nor) vs. hypoxia (hy) as a result of experiments performed
in Fig. 3b
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SMAD2 decrease is unrelated to TGFΒR2 expression. In
addition, Western blot analysis verified that the expres-
sion of SMAD7 increased by TGFß at 15 to 30 min, de-
creased after 1–2 h and remained low up to an 8 h
incubation period. However, SMAD7 protein expression
was similarly affected by TGFß supplied under normoxia
and hypoxia (Fig. 2e, f ). Thus, it appears that neither the
expression of TGFBR2 nor of SMAD7 account for the
specific effects of hypoxia seen at the level of SMAD2.
Next, we considered phosphatases to decrease SMAD2
phosphorylation. It was reported that PP2A dephosphor-
ylates p-SMAD3 under hypoxia [24]. Supplying the
PP2A inhibitor okadaic acid (OA) 1 h prior to addition
of TGFß for 8 h failed to rescue the decrease of phos-
horylated or total SAMD2 under TGFß/hypoxia (Fig. 2h).
Excluding SMAD2 activation or dephoshorylation as an
explanation for its decreased protein amount, we went
on to analyze SMAD2 mRNA. In general, protein ex-
pression is either regulated by an altered mRNA expres-
sion, reduced translation, and/or enhanced degradation.
SMAD2 mRNA expression was slightly induced but not
reduced by hypoxia (Fig. 3a). Therefore, we examined
protein stability by suppressing translation using 10 μg/
ml cycloheximide (CHX). SMAD2 was degraded faster,
comparing hypoxia to normoxia (Fig. 3b). The half-life
of SAMD2 under normoxia/TGFß was calculated to be
8.9 ± 1.2 h, while it was reduced to 5.1 ± 0.6 h under
hypoxia/TGFß (Fig. 3c). In conclusion, SMAD2 is desta-
bilized under hypoxia in TGFß-stimulated macrophages.
SMAD2 degradation under hypoxia is facilitated by
calpain
Considering increased degradation of SMAD2 under
TGFß/hypoxia, we analyzed pathways being involved.
Using bafilomycin A1 to inhibit lysosomal functions,
SMAD2 degradation remained unaffected thus, ruling
the involvement of the lysosomal compartment out
(Fig. 4a, b). We then used MG132 to block proteasomal-
and calpain-dependent degradation systems. MG132 res-
cued SMAD2 degradation in response to TGFß/hypoxia,
while lactacystin, a more specific proteasomal inhibitor,
not affecting calpain, failed to restore SMAD2 expres-
sion under these conditions (Fig. 4c-f ). Calpain is a
calcium-dependent non-lysosomal cysteine proteolytic
system that comprises a small regulatory subunit
(CAPNS1, also known as calpain reg) and a large cata-
lytic subunit (μ-calpain/m-calpain, also known as
CAPN). We tested mRNA expression of CAPNS1 in
macrophages stimulated with TGFß under normoxia and
hypoxia. CAPNS1 mRNA was significantly upregulated
by hypoxia or hypoxia/TGFß compared to normoxia or
TGFß-stimulation (Fig. 4g). The mRNA increase became
also apparent at the protein level (Fig. 4h). Expression ofthe catalytic subunit (CAPN1) was not affected by TGFβ
or hypoxia nor their combination (Fig. 4i). Following
macrophage activation with hypoxia/TGFß, holo-calpain
(80KD) is proteolytically processed and the removal of 14
or 28 amino acids forms active calpain. Western blot ana-
lysis detected active calpain in macrophages stimulated
with TGFß/hypoxia but not with TGFβ or hypoxia alone
(Fig. 4j). Experiments with the specific calpain inhibitor 1
CPI (10 μM), showed that decreased SMAD2 expression
seen under hypoxia/TGFß was fully recovered when
calpain activity was blocked (Fig. 4k). Conclusively, in
TGFß-stimulated macrophages hypoxia promotes degrad-
ation of SMAD2 by increasing calpain activity.
To explore how hypoxia affects TGFß-induced tran-
scriptional activity, we used a SMAD-specific reporter
assay. Due to difficulties in transfecting primary human
macrophages we used the J774A.1 mouse macrophage cell
line, which responded with SMAD2 phosphorylation in
Fig. 4 (See legend on next page.)
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Fig. 4 SMAD2 degradation under hypoxia is facilitated by calpain. a-f Macrophages were stimulated with TGFß under normoxia vs. hypoxia for
8 h in the presence of bafilomycin a, b, MG132 c, d, or lactacystin e, f. 2 h after TGFß, inhibitors were added and incubations went on for 6 h.
Western blot analysis and statistical evaluation is presented. g mRNA expression of the calpain regulatory subunit (CAPNS1) was analyzed by
quantitative PCR in macrophages exposed for 8 h to TGFß under normoxia (nor) vs. hypoxia (hy). h Western blot analysis of the calpain
regulatory subunit after exposure to TGFß and/or hypoxia for 8 h. i mRNA expression of the calpain 1 catalytic subunit (CAPN1) was analyzed
by quantitative PCR in macrophages exposed for 8 h to TGFß under normoxia (nor) vs. hypoxia (hy). j Proteolytic cleavage of CAPN1 under
TGFß/hypoxia was followed in macrophages by Western blot analysis after 8 h. k Macrophages were exposed to the calpain inhibitor 1 (CPI)
to follow SMAD2 degradation after stimulating cells for 8 h with TGFß under normoxia vs. hypoxia
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expression with TGFß/hypoxia under longer exposure
times (Additional file 1: Figure S1C, D). Stimulation of
J774A.1 cells, transfected with the SMAD reporter plas-
mid SEB4-Luc, with TGFß under hypoxia significantly re-
duced transcriptional activity compared to TGFß supplied
under normoxia (Fig. 5a). We then analyzed expression ofFig. 5 Hypoxia reduces SMAD2-dependent transcription. a TGFß-induced tran
binding element coupled to luciferase) as well as a Renilla-Luc plasmid. Stimu
expression of b thrombospondin1 (TSP1), c dystonin DST, d matrix metallopro
1 (PAI1) was analyzed by quantitative PCR in macrophages exposed for 8 h toSAMD2 and SMAD3 target genes in primary human mac-
rophages. Thrombospondin 1 (TSP1), dystonin (DST),
and matrix metalloproteinase 2 (MMP2) were reported to
be selectively regulated by SMAD2 [25–27] and we con-
firmed their responsiveness to TGFβ (Fig. 5b, c, d). Induc-
tion was significantly reduced in macrophages stimulated
with TGFβ at 1 % O2, reflecting the reduced expression ofscriptional activity in J774A.1 cells transfected with a SBE4-Luc (4xSMAD
lation was with TGFß under normoxia (nor) vs. hypoxia (hy) for 8 h. mRNA
teinase (MMP2), e cystatin (CST6), and (f) plasminogen activator inhibitor
TGFß under normoxia (nor) vs. hypoxia (hy)
Cui et al. Cell & Bioscience  (2015) 5:36 Page 8 of 12SMAD2. In contrast induction of SMAD3 target genes
such as cystatin (CST6) and plasminogen activator inhibi-
tor 1 (PAI1) [25] was not reduced under hypoxia (Fig. 5e,
f ). Apparently, only transcriptional responses of SMAD2
are selectively reduced by hypoxia in TGFβ-stimulated hu-
man macrophages.
Discussion
In human macrophages, in contrast to epithelial and
parenchymal cells [17, 18], periods of 8 h hypoxia or
longer reduced TGFß-induced SMAD2 activation. De-
creased phosphorylation of SMAD3, but not SMAD2,
under hypoxia was noticed in HeLa cells and attributed to
protein phosphatase 2A (PP2A) directly interacting with
SMAD3 [24]. In macrophages the decrease of p-SMAD2
was not due to PP2A activation, altered TGFBR2 receptor
activation, or inhibitory SMAD7 expression, but rather re-
sulted from hypoxia-evoked destabilization of SMAD2.
Regulation of SMAD2 degradation is complex. Smurf2 is
an E3 ubiquitin ligase, directly interacting with activated
SMAD2 and promoting its proteasomal degradation.
Neural precursor cell expressed developmentally down-
regulated protein 4–2 (NEDD4-2), another E3 ubiquitin
ligase like Smurf1 or 2, binds SMAD2 and SMAD3 but
exclusively degrades SMAD2 [21]. In addition, TGFβ-
induced factor homeobox 1 (TGIF) interacting ubiquitin
ligase 1 (Tiul1), induces SMAD2 to bind TGIF, which trig-
gers SMAD2 degradation [22]. Our data add proteolysis
by the calpain system also to account for alterations in the
SMAD2 protein amount. Interestingly, Lo and coworkers
studied the proteasomal degradation of SMAD2 [28].
Along our observations, their results suggested that lacta-
cystin cannot rescue a SMAD2 decrease to the same
extent as MG132, although they did not consider the cal-
pain system.
The calpain system consists of a catalytic subunit
(μ-calpain/m-calpain) and a common regulatory subnu-
nit CAPNS1 as well as the inhibitory subunit calpastatin.
After calcium binding, calpastatin detaches from the
protein complex and calpain is activated by autolysis
[29]. The calpain system plays important roles in macro-
phages. IFNγ induces calpain mRNA and protein expres-
sion in U937 and THP1 cells [30]. Calpain cleaves iNOS
and thus, affects inflammatory responses [31]. There are
several reports that calpain activity is upregulated under
hypoxia, with platelets being one typical example [32–35].
Hypoxia-induced thrombogenesis is associated with
CAPNS1-dependent calpain activation in the platelet acti-
vation cascade [35]. In line, we noticed increased calpain
activity under TGFβ/hypoxia by upregulating CAPNS1 in
macrophages. The calpain regulatory subunit functions
like a chaperone, assisting the catalytic subunit to fold
properly [36]. We showed that combining TGFß and
hypoxia is necessary to activate calpain in humanmacrophages as indicated in Fig. 4j, while hypoxia alone
did not activate calpain. This is in line with findings show-
ing that ischemia/hypoxia provokes an influx of Ca2+ into
the cell [32, 35], but the Ca2+ increase is not sufficient to
activate calpain [29, 37]. It is well established that TGFß
could also increase the influx of Ca2+ into cells [38]. Pre-
sumably, a high expression of CAPNS1 and the influx of
Ca2+ by the combined stimulation, hypoxia plus TGFß,
promotes activation of calpain. Calpain digests proteins at
a limited number of cleavage sites producing large poly-
peptide fragments rather than small peptides or amino
acid [29]. Early studies suggested that preferred residues
of the cleavage P2 position are Leu, Thr, and Val, and in
the P1 position are Lys, Thr, and Arg [39]. Following the
P2-P1 rule, SMAD2 has 17 potential cleavage sites. In
addition, calpain prefers small hydrophilic Ser residue at
the P1’ position. Considering this preference, there are still
4 possible cleavage sites at K46, Y101, R108, Y266 for cal-
pain in SMAD2. On the other hand, there are indications
that the specificity for calpain is not exclusively governed
by amino acid but rather by the 3D conformation of the
substrates [29, 39]. Using currently available online tools
at http://calpain.org for calpain substrates, amino acids at
sites 166, 395, and 6 are the top 3 predicted cleavage sites
with a score of 0.39, 0.39, 0.37 respectively [40]. For the
identification of the accurate cleavage sites more experi-
ments are needed that would be beyond the scope of this
work.
Our experimental conditions aimed to simulate condi-
tions macrophages are facing when entering the tumor
microenvironment, facing hypoxia and TGFß [41].
SMAD2 and SMAD3 have distinct transcriptional roles in
the tumor [27, 42, 43]. SMAD2 provokes secretion of anti-
angiogenetic factors, such as thrombospondin 1 (TSP1,
Fig. 5) as well as the VEGF-A antagonist sFlt-1, whereas
SMAD3 induces the secretion of pro-angiogenetic factor,
i.e., VEGF-A or plasminogen activator inhibitor 1 (PAI1,
Fig. 5), promoting angiogenesis when SMAD2 is inactive
[26, 44]. In addition, TSP1 overexpression in tumor cells
enhances the recruitment of pro-inflammatory macro-
phages and reduces tumor growth [45]. Conditional
medium of SMAD2 knockdown fibroblast induces prolif-
eration and in vivo deletion of SMAD2 in tumor cells gen-
erates a more aggressive phenotype compared to controls
[26]. The decrease of SMAD2 under TGFβ/hypoxia in
tumor-associated macrophages may add to their roles sup-
porting angiogenesis and tumor progression.
Angiogenesis influences tumor growth but also en-
ables metastasis [46]. Metastasis is a complex process
requiring invasive growth of tumor cells, epithelial to
mesenchymal transition (EMT), induction of angiogen-
esis, intra- and extravasation, and tumor growth at the
secondary sites [47]. Matrix metalloproteases (MMPs)
like MMP2 coordinate multiple steps of this process. In
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lar matrix remodeling and releasing growth factors like
VEGF from the matrix. MMP2 was also implicated in
endothelial cell apoptosis [46, 48]. As full activation of
MMP2 by the membrane type (MT)1-MMP provokes
endothelial cell death and expression of MMP2 in
endothelial cells and macrophages is reduced in acute
hypoxia (Fig. 5d), one might speculate that this reduc-
tion prevents endothelial cell death under hypoxia
when angiogenesis is usually enhanced [48, 49]. Other
TGFß-induced genes involved in metastasis are en-
hanced under hypoxia since SMAD3 target genes like
PAI-1 or CST6 (Fig. 5) are regulated by the hypoxia-
inducible factor (HIF) as well [16, 50]. In a previous
study we used ChIP-seq technology to identify HIF-1
and HIF-2 binding sites in primary human
macrophages and identified, amongst others, CST6 and
PAI-1 [23]. Apparently, in these cases TGFß/hypoxia
enhances rather than decreases gene expression in
macrophages. Thus, specifically attenuating SMAD2
under TGFß/hypoxia might have functional roles on
macrophages biology and tumor progression.Fig. 6 Graphical abstract. TGFβ binds to its receptor (TGFβR1 and TGFβR2), in
like SMAD2. Active SMAD2 translocates to the nucleus to provoke expression
TGFβ activates calpain to degrade SMAD2, which in turn attenuates SMAD2-d
TSP1, DST, and MMP2Conclusion
Our results indicate that hypoxia attenuates SMAD2
activation in TGFβ-stimulated macrophages (Fig. 6).
Mechanistically, this results from degradation of SMAD2
by calpain.
Material and methods
Cell culture and incubation procedures
If not indicated otherwise, all chemicals were pur-
chased from Sigma (Steinheim, Germany), while cell
lines came from ATCC (LGC Promochem, Wesel,
Germany). J774A.1 cells were cultured in Dulbecco’s
Modified Eagle Medium with 10 % fetal calf serum, 100
U/ml penicillin, and 100 μg/ml streptomycin (PAA
Laboratories, Cölbe, Germany). Primary human mono-
cytes were isolated from 50 ml buffy coats (DRK
Blutspendedienst Baden-Württemberg-Hessen, Frankfurt,
Germany). Blood was layered on a Ficoll-Isopaque
gradient (P = 1077 g ml−1). The interphase containing
peripheral blood mononuclear cells was obtained after
centrifugation (800 × g, 20 min). Cells were recovered,
washed twice in PBS, and left to adhere on culture dishesduces phosphorylation of TGFβR1 and downstream signaling molecules
of target genes, i.e., TSP1, DST, and MMP2. Hypoxia in combination with
ependent transcriptional activation and thus, diminishes the induction of
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Non-adherent cells were removed. The medium was chan-
ged to fresh RPMI 1640 medium, supplemented with 3 %
(v/v) human plasma (HP), 2 mM L-glutamine, 100 U/ml
penicillin, and 100 μg/ml streptomycin (PAA Laboratories,
Cölbe, Germany). Cells were kept at 37 °C in a humidified
atmosphere with 5 % CO2. Monocytes were differentiated
with human plasma for 6–8 days before they were treated
with 10 ng/ml TGFß. Purity of macrophage cultures was
about 90 %. To establish hypoxic conditions cells were in-
cubated in a hypoxic workstation with 1 % O2, 94 % N2,
5 % CO2 (Invivo2 400, Ruskinn Technology, Leeds U.K.).
Protein stability was assessed by stimulating macrophage
with TGFß for 4 h, followed by 10 μg/mL cycloheximide
(CHX). Samples were harvested after additional 1, 2, 3, or
4 h. Degradation of SMAD2 was followed by the addition
of 10 μM lactacystin, 10 μM MG132 (Z-Leu-Leu-Leu-al),
or 50 μM bafilomycin A1. After 2 h incubations with
TGFß co-incubations with TGFß and inhibitors went on
for 6 h. Phosphatase PP2A was inhibited by 10 μM oka-
daic acid (OA), preincubated for 1 h. 10 μM calpain in-
hibitor 1 was added simultaneously together with TGFß to
macrophages.
Transfection of primary human macrophages
For siRNA transfections human macrophages were
seeded in 6-well plates as described above. 50 nM siRNA
against HIF-1α (ON-TARGETplus SMART pool, Human
HIF1A, Thermo Scientific, Karlsruhe, Germany), HIF-2α
(ON-TARGETplus SMART pool, Human EPAS1, Thermo
Scientific), or non-targeting siRNA pool (GE Healthcare
Dharmacon) was used with 16.8 μl HiPerfect (Qiagen,
Hilden, Germany) in 500 μl medium with penicillin and
streptomycin for each well. After adding the mix, cells
were incubated for 24 h. Then medium was removed and
replaced by medium containing penicillin, streptomycin
and human serum to start experiments.
Western blot analysis
Cells were lysed in lysis-buffer (6.65 M urea, 10 % gly-
cerol, 1 % SDS, 10 mM Tris/HCl pH 6.8, pH was
adjusted to 7.4) and sonicated. After centrifugation
(16.000 × g, 10 min) the protein content in the super-
natants was determined by a protein assay kit (Bio-Rad,
Munich, Germany), 70 μg total protein was separated
on 10 % SDS gels and blotted on nitrocellulose mem-
branes. The following antibodies were used: human
pSMAD2 (#3108, Cell Signaling Technology), human
pSMAD3 (ab52903, Abcam), human SMAD7 (ab124890
Abcam), human SMAD2/3 (#3102 Cell Signaling Tech-
nology), human calpain regulatory subunit (sc-32785,
Santa Cruz), CAPN1 (C5736, Sigma), nucleolin (sc-13057,
Santa Cruz), and ß-tubulin (T4026, Sigma). Horseradish
peroxidase-conjugated goat anti-rabbit or anti-mouse IgG(Sigma) were used as secondary antibodies. Densitometry
was performed using image J software (http://rsbweb.nih.
gov/ij/). Briefly, rectangles were used to assess signal
strength of each individual band and the background was
measured by using the baseline tool and subtracted from
individual values. Target protein expression was normal-
ized to the loading control i.e., tubulin or nucleolin.
Luciferase reporter activity
The SBE4-Luc reporter plasmid was a gift from Bert
Vogelstein (Addgene plasmid # 16495) [51], while the
renilla control vector pRL-SV40 was bought from Pro-
mega (Frankfurt, Germany). J774A.1 cells were transi-
ently transfected with 0.2 μg plasmid using JetPrime™
transfection reagent (Polyplus transfection, Illkirch,
France) according to the manufacturer's protocol. After
16 h, medium was changed and cells were starved for
2 h prior to stimulation. Afterwards, cells were lysed and
firefly as well as renilla luciferase activities were deter-
mined using a Dual Luciferase kit assay (Promega) on a
Mithras LB 940 luminometer (Berthold, Bad Wildbad,
Germany).
Flow cytometry (FACS)
For TGFΒR2 surface expression, single cell suspensions
were generated from detached macrophages by diges-
tion with accutase (PAA) for 10 min at 37 °C. 105 cells
were transferred to new tubes. Before staining, non-
specific antibody binding to Fcγ receptors was blocked
with Fcγ Block Receptor Binding Inhibitor (eBioscience,
Frankfurt, Germany) for 15 min on ice, followed by
staining with human TGFΒR2 fluorescein-conjugated
antibody (FAB241F,R&D Systems, Germany) using
standard protocols. We used an LSRFortessa Cell
Analyzer (BD, US) and results were analyzed using
FlowJo software 7.6.1 (Treestar, Ashland, OR, USA). To
discriminate macrophages from other non-leukocyte
cells, samples were stained with CD45 (BD Bioscience).
For daily instrument calibration we used Cytometer
Setup and Tracking beads (BD Biosciences).
mRNA isolation and quantitative PCR
Isolation of mRNA and quantitative PCR was performed
























Experiments for mRNA expression and flow cytometry
were performed in duplicate and repeated at least 3 times.
Western blot analysis was performed at least 3 times. Data
are expressed as means ± SEM. Multigroup statistically
significant differences were calculated after analysis of
one-way variance (ANOVA) and Bonferroni’s test. A sta-
tistically significant difference between two groups was
calculated by paired T test. Individual P values are given in
the figures (*P < 0.05, **P < 0.01, ***P < 0.001).
Additional file
Additional file 1: Figure S1. Western blot analysis of (A) HIF-1α and (B)
HIF-2α of primary human macrophages transfected with non-targeted
siRNA constructs (ctr), siRNA-HIF1α (si1α), or siRNA-HIF2α (si2α) exposed
to normoxia vs. hypoxia (1% O2) for 8 h. (C) Western analysis of phospho
SMAD2 in J774 cells, exposed to TGFß under normoxia vs. hypoxia (1%
O2) for 8 h. (D) Statistical analysis of data presented in Figure S1C.
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